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Abstract
Growing evidence has shown that adipose tissue accumulation is associated with bone 
metabolism. Arguably, adipokines, secretory proteins of adipose tissue, are involved in 
bone homeostasis including development and remodeling. The “classical” adipokine 
leptin regulates bone formation negatively and bone resorption positively via central 
nervous system. Leptin also stimulates directly osteoblastogenesis and inhibits osteo-
clastogenesis through stimulation of osteoprotegerin and inhibition of receptor acti-
vator for nuclear factor k B ligand (RANKL) expression in osteoblasts. Another major 
adipokine, adiponectin, and its receptor are expressed in osteoblasts. Adiponectin 
stimulates the proliferation, differentiation, and mineralization of osteoblastic cells, and 
indirectly stimulates osteoclast differentiation via enhancement of RANKL and inhibi-
tion of osteoprotegerin expression in osteoblasts, whereas directly inhibits osteoclast 
activity and bone resorption. Altogether, adipose tissue via adipokines plays a crucial 
role in the maintenance of bone homeostasis. These findings are reviewed herein.
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Introduction 
Osteoporosis has become a major 
medical problem in the last half cen-
tury, largely as the result of increased 
longevity and a changing lifestyle (1). 
Osteoporosis has been defined as a 
skeletal disease characterized by low 
bone mass and microarchitectural de-
terioration of bone tissue with a con-
sequent increase in bone fragility and 
susceptibility to fracture. The number 
of patients with osteoporosis is rapidly 
increasing especially in industrialized 
countries. It is very important to pre-
vent osteoporotic fractures because 
they frequently occur and enhance the 
mortality of the elderly people as high 
as 6- to 9-fold (2,3). It is reported that 
7% of survivors of all types of fracture 
have some degree of permanent disa-
bility and 8% require long-term nurs-
ing care (4). Overall, a 50-year-old 
woman has 13% chance of experienc-
ing functional decline after any frac-
ture. In addition to its effect on health, 
osteoporotic fracture has a huge im-
pact economically. 
In healthy adults, bone mass and 
turnover are maintained by coordi-
nated balance of two major types of 
cells: osteoblasts and osteoclasts. Os-
teoclasts move to resorb mature bone 
tissue and micro-damage constantly 
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(bone resorption), and then osteoblasts form new bone tissue in 
the lacunar pit (bone formation), controlling the reshaping and 
replacement of bone. A number of systemic and local factors are 
involved in the regulation, such as insulin, insulin-like growth 
factor-I (IGF-I), and bone morphogenetic proteins (BMPs) 
(5,6). However, the mechanism of bone remodeling is not fully 
understood to date. 
Recent studies have revealed that adipose tissue is not only 
an energy-storing, but also a secretory tissue producing a vari-
ety of biologically active proteins named adipokines (7). Grow-
ing evidence shows that there is a positive correlation between 
bone mineral density (BMD) and fat mass, and that fat accu-
mulation affects bone metabolism (8,9). Although mechanical 
loading may contribute to this relationship, other factors are also 
involved. Leptin and adiponectin have recently attracted wide-
spread attention, especially in the diabetes field, due to its ben-
eficial antidiabetic effect in the regulation of energy homeostasis 
and insulin sensitivity (10). Several studies suggest that leptin 
and adiponectin in the circulation are involved in bone metabo-
lism (11-13). Leptin, a 16 kD protein mainly secreted by white 
adipose tissue and strongly correlated positively with body fat 
mass, regulates various biological functions including appetite 
and reproduction (14,15). Leptin is reported to regulate bone 
mass accumulation via a hypothalamic relay. On the other hand, 
it is reported that mesenchymal progenitor cells and osteoblasts 
have functional leptin receptors, suggesting that leptin also di-
rectly regulates osteoblastogenesis and osteoblast differentiation. 
Another major adipokine, adiponectin, is specifically and high-
ly expressed in visceral and subcutaneous fat as well as in bone 
marrow fat depots and is abundantly present in plasma (16). It is 
a 30 kD polypeptide containing an N-terminal signal sequence, 
a variable domain, a collagen-like domain, and a C-terminal 
globular domain (17). Adiponectin receptor (AdipoR) has been 
identified, and the biological effects of adiponectin are mediated 
through the two adiponectin receptor subtypes, AdipoR1 and Ad-
ipoR2 (18), which belong to the seven-transmembrane-spanning 
receptor; the N-terminus is internal and the C-terminus is exter-
nal; an opposite topology to the other reported G protein-coupled 
receptors (19). Several studies have shown that adiponectin and 
its receptor are expressed in osteoblasts (20-22), suggesting that 
bone metabolism is affected by adiponectin. Furthermore, a few 
studies reported that other adipocytokines such as resistin and 
visfatin may be involved in bone metabolism. In addition, bone 
has recently emerged as an endocrine organ affecting adipose tis-
sue accumulation and glucose homeostasis through osteocalcin 
(9,23,24). In this review, I summarize the effects of adipokines, 
such as leptin, adiponectin, resistin, and visfatin, on bone cells 
and bone mass in vitro and in vivo. 
Leptin maintains bone homeostasis through the central 
nervous system 
Leptin is a major hormonal product of the adipose tissue that 
regulates appetite and reproductive function. Leptin acts as a 
satiety signal, working through the hypothalamus to stimulate 
feeding when leptin levels in circulation are decreased with low 
fat mass and to inhibit food intake when energy stores are plen-
tiful (25). Mouse obese (ob) gene encodes leptin (26). The gene 
is disrupted in the naturally occurring leptin-deficient mutant, 
ob/ob mice. The ob/ob mice are hyperphagic and suffer from 
obesity and type 2 diabetes because of lacking the satiety and 
insulin-sensitizing signal from leptin (27). Leptin receptors, a 
single-transmembrane-domain receptor of the cytokine recep-
tor family (28), are widely distributed in peripheral tissues, in-
cluding skeletal muscle, bone, and cartilage, but a primary target 
of leptin is the brain, specifically the hypothalamus. Another 
mouse model lacking leptin signaling, db/db mice, has a mu-
tated and inactive leptin receptor. As with the leptin-deficient 
ob/ob mouse, the phenotype of the db/db mouse is characterized 
by hyperphagia, obesity, hyperglycemia, and hyperinsulinemia 
(29). On the other hand, the bone phenotypes of the ob/ob and 
db/db mice are puzzling because there is some variability in the 
magnitude and direction among previous published research. 
Some investigators reported the mice lacking leptin receptor 
have low bone mass (30-33), whereas others showed high bone 
mass in the mice (34). The reasons for these discrepancies re-
main unclear. 
Ducy et al (34) previously reported that the ob/ob and db/db 
mice had higher trabecular bone mass associated with a higher 
mineral apposition rate (MAR) when compared with their wild-
type littermates, suggesting that leptin exerts a negative effect 
on bone formation and bone mass accumulation. These authors 
further explored the alteration of bone in the mice by showing 
that leptin acts on the skeleton through an indirect pathway via 
its hypothalamic relay. In fact, intracerebroventicular (ICV) in-
fusion of leptin (192 ng/day) for 28 days to the ob/ob mice nor-
malized their bone phenotypes. In addition, ICV leptin infusion 
in wild-type mice led to rapid bone loss in the vertebrae. It was 
demonstrated that an orexigenic protein, neuropeptide tyrosine 
(NPY), which is secreted by the hypothalamus and downregu-
lated by leptin in the satiety control loop, decreased bone mass 
when administrated intracerebroventicularly, and that deletion 
of its hypothalamus-specific receptors had opposite effects with 
increased bone mass (34,35). Furthermore, Takeda et al dem-
onstrated that leptin central antiosteogenic function was medi-
ated by the sympathetic nervous system (36). Leptin binds to 
receptors on the hypothalamus, inducing an increase in sym-
pathetic activity which signals to osteoblasts via the b2 adren-
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and neuropeptides such as neuromedin U, NPY, serotonin, and 
cannabinoid receptors are involved in bone metabolism (42,43). 
Further studies are thus necessary to understand the regulation 
of leptin in bone metabolism through the central nervous sys-
tem. 
Direct regulation of bone metabolism by leptin 
Previous studies have shown that mesenchymal stem cells and 
osteoblasts are targets for leptin action, as these cells express 
functional leptin receptors (44,45). Both two types of leptin re-
ceptors, short-form and long-form, are shown to be expressed 
on the surface of bone marrow stromal cells (BMSC) and osteo-
blasts (46). In response to leptin stimulation, rapid induction of 
phosphorylation of Stat3, a downstream of leptin signaling, was 
observed in the BMSC. 
The effects of leptin on proliferation of mesenchymal stem 
cells and osteoblastic cells were investigated by several groups. 
Takahashi et al (46) demonstrated that leptin stimulated the 
proliferation of C3H10T1/2, a mouse embryonic cell line, in a 
dose- and time-dependent manner. It was found that mitogen-
activated protein kinase (MAPK)-specific inhibitor PD98059 
completely blocked the increases in both MAPK activity and 
cell proliferation caused by leptin, suggesting that the stimula-
tory effect of leptin on cell growth of C3H10T1/2 is depend on 
MAPK pathway. Leptin caused a significant increase in the ac-
tivation of PI3-kinase that was accompanied by an increase in 
cell proliferation dose dependently (47). Leptin activated MAPK 
and PD98059 blocked DNA synthesis induced by leptin (46), 
whereas this adipokine increased the proliferation of isolated 
fetal rat osteoblasts comparably with IGF-I, a major anabolic 
factor of bone formation (48). Moreover, several in vitro stud-
ies examined the effects of leptin on the commitment of mesen-
chymal stem cells to osteoblast lineage and the differentiation of 
osteoblasts. Leptin increased mRNA and protein levels of ALP, 
type I collagen, and osteocalcin in dose- and time-dependent 
manner as well as enhanced mineralized matrix in human mar-
row stromal hMS2-12 cells (49). Leptin had the ability to up-reg-
ulate type I collagen gene expression in osteoblastic MG63 cells 
(50). Similar results are reported in other cell models as show-
ing increased cell growth of osteoblastic lineage and mineraliza-
tion by leptin (51-53). Furthermore, in vitro deletion of leptin 
receptor exhibited significant less mineral apposition compared 
with control bone marrow stromal cells (45). In addition, it is 
reported that leptin protected retinoic acid-induced apoptosis 
in primary human osteoblast cultures, leading to enhancement 
of osteoblastic activity (53). 
Although Takeda et al (36) reported that transgenic mice ex-
pressing leptin in osteoblasts had no overt bone abnormalities, 
ergic receptors presented at their surface. They also showed an 
evidence that b-adrenergic antagonist induced an increase in 
bone mass in the mice. It is suggested that the sympathetic sig-
nal stimulated by leptin inhibits osteoblast proliferation via the 
molecular clock regulation of c-myc and Cycline-D expression 
and promotes Rankl expression, while leptin increases the ex-
pression of Cart, a gene encoding cocaine amphetamine regu-
lated transcript (CART), in the hypothalamus, which increases 
Rankl expression (37). Taken together, these findings suggest 
that leptin has a negative impact on bone mass by inhibiting os-
teoblast proliferation and increasing osteoclast activity through 
the central nervous system and using two neural mediators, the 
sympathetic nervous system and CART. In contrast, Iwaniec et 
al (38) reported different central effects of leptin on bone mass 
as compared with that reported by Ducy et al (34). Iwaniec et al 
(38) demonstrated that ob/ob mice treated with a recombinant 
adeno-associated virus expressing leptin in the hypothalamus 
displayed increases in femoral bone mass and length as well as 
a decrease in cancellous bone volume. Moreover, blood osteoc-
alcin levels were increased in wild-type and ob/ob mice injected 
with the recombinant leptin-expressed adeno-associated virus, 
whereas basal osteocalcin levels in ob/ob mice were significantly 
lower as compared to those in wild-type mice (39). Bartell et 
al (40) showed that ICV injection of 0.38 mg/day and 1.5 mg/
day leptin for 12 days induced the expression of Runx2, osterix, 
and alkaline phosphatase (ALP) in femoral bone marrow and 
inhibited the expression of receptor activator for nuclear fac-
tor k B (RANK) and macrophage colony-stimulating factor. 
Moreover, whole-body BMD and body mineral content (BMC) 
as well as MAR were increased in the mice administrated in-
tracerebroventicularly. The apparent difference between Bartell 
et al’s and Ducy et al’s data may be due in part to the differences 
in doses administrated ICV (1.5 mg/day versus 192 ng/day) and 
the duration of treatment (12 days versus 28 days). In addition to 
Bartell et al’s findings, overexpression of leptin in hypothalamus 
increased femoral length and volume (38). Therefore, high dose 
administration of leptin ICV might have an anabolic effect on 
bone. However, it is suggested that leptin resistance may exist 
when having high concentration of leptin. Indeed, the leptin lev-
els in the circulation are positively correlated with body weight 
and fat mass, and obese patients have high blood leptin levels 
despite leptin has beneficial effects on the hyperphagia and gain 
of body weight. It is reported that leptin itself induces the leptin 
resistance in the hypothalamus (41). Therefore, the high dose 
administration and overexpression of leptin might induce the 
resistance to negative effects of leptin on bone mass. The cen-
tral regulation of bone mass is complex and incompletely un-
derstood. Previous studies showed that many neurotransmitters 
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several interventional studies examining the effects of peripher-
al leptin administration showed that leptin directly affects bone 
mass in different animal models. Leptin administration led to 
a significant increase in femoral length, total body bone area, 
BMC, and BMD in ob/ob mice as compared to vehicle treated 
controls (31). Further, such a treatment increased both tra-
becular and cortical bone mass and reversed the defect in bone 
growth and osteopenia, as measured by dual energy X-ray ab-
sorptiometry (DXA) and peripheral quantitative computerized 
tomography (qCT). Moreover, systemic daily administration of 
leptin to adult male mice reduced bone fragility by more than 
20% (48). Using tail-suspended female rats, a model of rapid 
bone loss characterized by an uncoupling pattern of bone re-
modeling, intraperitoneal leptin administration prevented tail-
suspension induced a progressive decrease in tibia-metaphysis 
BMD by DXA and a decrease in bone formation rate by histo-
morphometry (54). Administration of leptin to ovariectomized 
rats prevented the rapid bone loss induced by estrogen deficien-
cy (55). Of note, the combination of estrogen and leptin further 
decreased bone turnover compared with that in estrogen-treat-
ed ovariectomized rats. In addition, leptin increased osteoprote-
gerin (OPG) mRNA expression and protein production as well 
as decreased RANK ligand (RANKL) mRNA levels, leading to 
inhibition of osteoclastogenesis. In contrast, ovariectomized rats 
injected with a recombinant adeno-associated virus expressing 
leptin in the hypothalamus showed no change in bone volume 
by micro-CT and histomorphometry compared with ovariecto-
mized rats (56). Taken together, these studies by peripheral ad-
ministration of leptin suggest that leptin is able to directly and 















Figure 1. Schematic representation of the direct and indirect effects of leptin on bone metabolism. Leptin secreted from 
adipocytes binds to its receptor expressed in the hypothalamus and stimulates sympathetic nervous system, leading to inhibi-
tion of bone formation via β2 adrenergic receptors as well as activation of bone resorption via RANKL expression in osteoblasts. 
Leptin also increases CART expression in the hypothalamus, which promotes RANKL expression. On the other hand, leptin di-
rectly stimulates osteoblastogenesis and bone formation via leptin receptor and inhibits osteoclast differentiation via inhibition 
of RANKL expression. 
LR, leptin receptor; vMH, ventromedial hypothalamic nucleus; SNS, sympathetic nervous system; CART, cocaine amphetamine 
regulated transcript; β2AR, β2 adrenergic receptor; RANKL, receptor activator for nuclear factor κ B ligand. Red arrow indicates 
direct effect of leptin. Black arrow indicates indirect effect of leptin.
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Adiponectin regulation of bone mass 
It has been shown that adiponectin is expressed in osteoblastic 
cells. Adiponectin mRNA expression and its protein secretion 
are detectable in vitro in osteoblasts and in vivo in mandibu-
lar bone of rat (57). Furthermore, adiponectin is also found in 
bone marrow-associated adipocytes (58), and the adiponectin 
level is higher in diluted bone marrow fluid than in the serum 
of rats (59). These facts suggest that adipocytes as well as bone 
cells contribute to the production and high concentration of adi-
ponectin found in bone marrow. On the other hand, although 
the mRNA of AdipoR1 and AdipoR2 is expressed in primary 
human osteoblasts (57,59), AdipoR1, but not AdipoR2, protein 
is detectable by Western blot assay (59). We also confirmed that 
MC3T3-E1 cells expressed only AdipoR1 (20). These findings 
suggest that adiponectin carries signals and plays a role in bone 
tissue through the autocrine, paracrine, and endocrine path-
ways. 
The stimulatory effect of adiponectin on osteoblast prolifera-
tion has been reported by several research groups (56,58-60). 
Luo et al (58) demonstrated that adiponectin promotes osteo-
blast proliferation and that suppression of AdipoR1 by small-
interfering (siRNA) abolished adiponectin-induced cell pro-
liferation. In addition, adiponectin activated c-jun N-terminal 
Kinase (JNK), and the stimulatory effect of adiponectin on cell 
growth was blocked by the siRNA of AdipoR1 and a JNK inhibi-
tor. We also confirmed that adiponectin treatment significantly 
stimulates the proliferation of MC3T3-E1 cells (59). The central 
modulator of the signaling cascade triggered by the adiponectin 
receptor is adenosine monophosphate-activated protein kinase 
(AMPK), which plays a key role in energy homeostasis and all 
metabolic effects exerted by the hormone and energy homeo-
stasis (61). In our experiments, adiponectin stimulated AMPK 
phosphorylation in osteoblasts and AMPK activation by amino-
imidazole-4-carboxamide ribotide, a pharmacological activator 
of AMPK known as AICAR, induced cell proliferation (59,62). 
Therefore, adiponectin stimulates cell growth of osteoblasts via 
activation of the JNK and AMPK pathways. Furthermore, sev-
eral in vitro studies have shown that adiponectin has a stimula-
tory action on the differentiation of osteoblasts and induces os-
teoblastic differentiation of mesenchymal progenitor cells. It was 
previously demonstrated that adiponectin treatment increased 
ALP activity, osteocalcin and type 1 collagen production, and 
mineralized matrix in dose- and time-dependent manners (58). 
We also demonstrated that reduction of AdipoR1 expression by 
siRNA of AdipoR1 decreased mRNA expression of type 1 col-
lagen and osteocalcin, ALP activity, and the mineralization de-
fined by von Kossa and Alizarin red stainings in MC3T3-E1 cells 
(59). Adiponectin increased mRNA and protein levels of BMP-2 
in cultured osteoblastic cell lines, MG-63 and hFOB (63), and 
the adiponectin-induced BMP-2 expression was attenuated by 
the siRNA of AMPK and AMPK inhibitors. Adiponectin stimu-
lated BMP-2 and Runx2 expression and induced the commit-
ment of mesenchymal stem cells into an osteoblast lineage as 
well as the differentiation of osteoblasts (64). Furthermore, we 
found that adiponectin stimulated the expression of osterix (59), 
an essential osteogenic transcription factor downstream of the 
BMP-2 signaling pathway; osterix promoter activity is also in-
creased by adiponectin treatment (65). These findings confirm 
that BMP-2 signaling molecules are involved in the stimulatory 
effect of adiponectin on osteoblasts.
It is reported that adiponectin receptor is expressed in not 
only osteoblasts but also osteoclastic cells (66) and that adi-
ponectin directly inhibits osteoclastogenesis and bone resorp-
tion. Treatment of osteoclastic cells with adiponectin after M-
CSF/RANKL-induced differentiation resulted in a significant 
reduction of the resorption area in a dose-dependent manner 
(67). Adiponectin has an inhibitory effect on osteoclast forma-
tion using a mouse macrophage-like cell line, RAW264 (68). 
In addition, suppression of AMPK activity abrogated the in-
hibition of nuclear factor of activated T cells 2 (NFAT2) (also 
known NFATc1) expression by adiponectin treatment (69). Adi-
ponectin treatment dramatically inhibits the induction of the 
osteoclastogenic regulators such as NFAT-2, cathepsin K, and 
tartrate-resistant acid phosphatase (TRAP) by RANKL and the 
mRNA level of tumor necrosis factor (TNF) receptor-associated 
factor 6 (TRAF6) (65). Adiponectin was also found to increase 
osteoclast apoptosis and decrease proliferation of osteoclast pre-
cursor cells. It was demonstrated that osteoclastogenesis was 
significantly inhibited by adiponectin in primary mouse bone 
marrow cultures, while no effects of adiponectin were observed 
on RAW-264 cells treated with RANKL or on isolated mature 
osteoclasts, suggesting that adiponectin inhibits osteoclast for-
mation but has no effect on mature osteoclast activity (70). In 
contrast, Shinoda et al (66) reported that the number of cultured 
osteoclasts isolated from adiponectin knockout mice showed no 
difference compared with wild-type cells. On the other hand, 
adiponectin regulated bone turnover via enhancing RANKL 
expression and suppressing OPG in osteoblasts although adi-
ponectin treatment had no direct effect on these cells (71). Adi-
ponectin treatment induced RANKL and inhibited OPG mRNA 
expression in a dose- and time-dependent manner. Suppression 
of AdipoR1 with siRNA abolished the adiponectin-regulated 
RANKL and OPG mRNA expression, and pretreatment of os-
teoblasts with a p38 MAPK inhibitor abolished adiponectin-
regulated RANKL and OPG mRNA expression. They also found 
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that adiponectin induced osteoclast formation in the co-culture 
systems of osteoblasts and human osteoclast-like cells and that 
OPG entirely blocked this response. Overall, although a few 
studies reported no effect of adiponectin on osteoclasts, most 
other in vitro studies showed that adiponectin inhibits osteoclast 
activity and bone resorption, while adiponectin accelerates bone 
turnover via enhancement of RANKL and inhibition of OPG in 
osteoblasts. 
However, several in vivo studies using overexpression and 
knockout models of adiponectin show conflicting results. Over-
expression of adiponectin in the liver enhanced bone formation 
and showed a gain of bone mass compared with wild-type mice 
(67,72), whereas adiponectin-overexpressing mice had a signifi-
cantly lower bone mass and that the peak load of femur neck 
and vertebra was significantly lower than wild-type mice (73). 
There is not significant differences in bone mass or turnover in 
adiponectin-overexpressing mice in the liver or in adiponectin 
knockout mice compared with their littermates (66). It is well-
known that adiponectin enhances insulin activity and reduces 
insulin resistance. Most studies have consistently shown that 
adiponectin knockout mice have either spontaneous or diet-
induced insulin resistance with hyperinsulinemia (74), which 
affects bone metabolism and causes an increase in bone mass. 
Adiponectin also plays important roles in the liver, muscle, pan-
creas, and hypothalamus, which might affect bone metabolism. 
In addition, because adiponectin receptors are ubiquitously ex-
pressed in various tissues, adiponectin may have both direct and 
indirect effects on bone. Therefore, regarding the conflict results 
of these in vivo studies, physiological compensation and adapta-
tion might contribute to the complexity of the in vivo role of 
adiponectin in bone metabolism. On the other hand, Tu et al 
(70) reported that femurs harvested from mice were transplant-
ed into adiponectin knockout and wild-type mice. In the study, 
the growth of bone explants in adiponectin knock-out mice was 
significantly retarded, and micro-CT and histological analysis 
revealed reduced trabecular bone volume, decreased cortical 
bone, and increased osteoclast number in bone explants in adi-
ponectin knock-out mice. Their findings propose the benefits of 
avoiding the long term adaptation and compensation mecha-
nism, which might be seen in knockout and transgenic overex-
pression mice. In addition, Jiang et al (75) examined the effect of 
intermittent adiponectin administration on bone regeneration 
following distraction osteogenesis. In their experiments, rapid 
unilateral mandibular osteodistraction was performed on New 
Zealand white rabbits, and adiponectin or a vehicle was inject-
ed into the distraction gap. Under rapid distraction, immature 
bone formation was observed in the distracted callus from the 
control group, whereas DXA revealed greater bone formation 
and higher BMD and BMC of the distracted callus in the group 
with administration of adiponectin. Micro-CT, histological, and 
mechanical strength analyses also confirmed increased bone 
volume and greater strength of the mandible in the adiponectin 
treatment group compared with controls. These studies indicate 
that adiponectin might be a potential target for combating bone 
loss in bone metabolic disorders such as osteoporosis and also 
for healing bone fractures. 
The effects of resistin and visfatin on osteoblasts and os-
teoclasts 
Resistin is a 12.5 kD or 10 kD cysteine-rich polypeptide 
hormone and originally named for its ability to induce insulin 
resistance (76,77). Resistin is expressed mainly from mature 
adipocytes in rodents, whereas in humans it is produced pre-
dominantly in inflammatory cells, especially in macrophages 
(78). It was found that resistin is expressed with the highest con-
centration in bone marrow. Previously, Thommesen et al (79) re-
ported that resistin is expressed in osteoblastic and osteoclastic 
cells and involved in their differentiation. The mRNA of resistin 
was expressed in not only adipocytes but also MC3T3-E1, RAW 
264.7, and primary human osteoblasts. The protein was also 
detectable in these cells by Western blot analysis. Recombinant 
resistin increased the number of differentiated osteoclasts and 
stimulated nuclear factor k B promoter activity. Also, resistin en-
hanced the proliferation of MC3T3-E1 cells in a PKA- and PKC-
dependent manner as well as the expression of interleukin-6 in 
the cells, which is stimulator of osteoclast differentiation (80). 
These results suggest that resistin induces osteoclast activity di-
rectly and indirectly through stimulation of interleukin-6 (IL-6) 
expression in osteoblasts, leading to a reduction of bone mass. 
Visfatin, also known as pre-B cell colony-enhancing factor 
(PBEF) and nicotinamide phosphoribosyltransferase (Nampt)], 
is a 52 kD cytoplasmic protein abundantly produced by adipose 
tissue (81), and its expression in adipocytes and its concentra-
tion in plasma increase with obesity and type 2 diabetes (82). 
Visfatin binds to and activates the insulin receptor, thereby ex-
erting insulin-mimetic effects as lowering blood glucose level 
(81). It has been shown that osteoblasts have a functional insu-
lin receptor and that insulin stimulates collagen synthesis and 
differentiation of osteoblasts (83,84). Indeed, deletion of insulin 
receptor in osteoblasts induced decreases in ALP activity and 
osteocalcin expression by suppressing a Runx2 inhibitor, Twist2 
(85). Moreover, osteoblast-specific insulin receptor knockout 
mice displayed reduced bone accumulation due to decreased 
bone formation and deficient numbers of osteoblasts. It is thus 
assumed that visfatin carries signals from adipose tissue to bone 
and has an anabolic effect on bone mass. Visfatin phosphorylated 
insulin receptor, insulin substrate (IRS)-1, and IRS-2 in primary 
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cultures of normal human osteoblast (86). Visfatin stimulated 
glucose uptake in the cells. It was observed that cell growth, ALP 
and type I collagen expression, as well as mineralization were 
enhanced by visfatin treatment. In addition, they showed that 
the effects of visfatin were similar to insulin and that the stimu-
latory effects of visfatin were completely abolished by a specific 
inhibitor of insulin receptor tyrosine kinase activity. However, 
it was found that both visfatin and insulin inhibited osteocalcin 
secretion from the human osteoblastic cells. Moschen et al (87) 
reported that visfatin also affects osteoclasts. Visfatin treatment 
significantly inhibited osteoclast formation induced by RANKL 
and M-CSF in a dose-dependent manner. Moreover, suppres-
sion of mRNA expression of RANK, NFATc1, and Cathepsin-
K by visfatin was observed in osteoclastic cells. Taken together, 
visfatin stimulates the proliferation and differentiation of osteo-
blasts through activation of insulin receptor and inhibits osteo-
clastogenesis, suggesting that visfatin has beneficial effects on 
bone mass. 
Endocrine loop between bone and adipose tissue
In addition to its classical functions in biomechanical homeo-
stasis, bone has recently been regarded as an endocrine organ. 
Osteocalcin, one of the osteoblast-specific secreted proteins, has 
several hormonal features and is secreted into the general circu-
lation by osteoblastic cells. It has been shown that serum osteo-
calcin (uncarboxylated form) has a beneficial effect on glucose 
and fat metabolism (88,89). Osteocalcin increases the expres-
sion of insulin in pancreatic b cells as well as that of adiponectin 
in adipocytes, resulting in preventing the development of met-
abolic diseases, obesity, and type 2 diabetes in wild-type mice 
(89). Recently, insulin receptor signaling in osteoblasts is shown 
to control osteoblast development and osteocalcin expres-
sion and regulate peripheral adiposity and glucose metabolism 
(90,91), indicating the existence of a bone-pancreas endocrine 
loop through the function of insulin and osteocalcin. Since the 
previous studies described above have shown that adiponectin 









Figure 2. Schematic representation of the regulation of bone metabolism by adiponectin. Adiponectin and adiponectin 
receptor type 1 are expressed in osteoblasts. Adiponectin stimulates osteoblastogenesis and bone formation via the receptor. 
Adiponectin enhances the expression of RANKL and inhibits that of OPG, resulting in an activation of osteoclasts. On the other 
hand, adiponectin directly inhibits bone resorption. AdipoR1, adiponectin receptor type 1; RANKL, receptor activator for nuclear 
factor κ B ligand; OPG, osteoprotegerin. 
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teocalcin stimulates the expression of adiponectin in adipocytes, 
it is rational to hypothesize that an endocrine loop modulated by 
the activity of adiponectin and osteocalcin exists between bone 
and adipose tissue. On the other hand, leptin and resistin coor-
dinate bone remodeling as described above. However, previous 
studies showed that osteocalcin did not affect the expression of 
leptin or resistin in adipose tissue (87,92). Therefore, these two 
adipokines might not be involved in the function of osteocalcin 
on glucose metabolism. 
Conclusion
Accumulating evidence indicates that adipokines are involved 
in bone metabolism. Leptin negatively regulates bone mass ac-
cumulation via the central nervous system, whereas leptin has 
direct positive effects on bone formation and remodeling. Sys-
temic leptin administration induces a gain of bone mass, sug-
gesting that leptin in the circulation may have a beneficial ef-
fect on bone growth and BMD. Adiponectin stimulates osteo-
blastogenesis and differentiation of osteoblasts through BMP-2 
expression, and may affect osteoclast activity. Moreover, adi-
ponectin enhances osteocalcin expression in osteoblasts, while 
osteocalcin alternatively stimulates adiponectin expression in 
adipocytes. Therefore, it is assumed that an endocrine loop may 
exist between bone and adipose tissue through adiponectin and 
osteocalcin. Furthermore, a few studies demonstrated that resis-
tin and visfatin might affect bone metabolism. Further studies 
are necessary to understand the cross-talk between adipose tis-
sue and bone. 
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